Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial영국에서 2 가지 용량의 Chadox1 NCOV-19 또는 BNT162B2에 따른 3 가지 용량 (부스터)으로서 7 개의 코비드 -19 백신의 안전성 및 면역 원성Clinical Trial Published on 2021-12-182022-08-13 Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상, [키워드] 95% CI Ad26 Ad26.COV2.S adverse event age anti-Spike IgG antibody assigned blinded BNT BNT162b2 booster booster vaccination booster vaccines cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Control control group control groups Course COV-BOOST COVID-19 COVID-19 vaccine CureVac CVn CVnCoV dose eligibility criteria ELISA female finding FIVE funding generate geometric mean geometric mean ratio geometric mean ratios GMR GMRs group humoral Humoral and cellular responses immunogenicity individuals initial intention-to-treat population investigated IQR ISRCTN janssen laboratory-confirmed SARS-CoV-2 infection Local m1273 median age MenACWY meningococcal conjugate vaccine Moderna modified intention-to-treat mRNA1273 multicentre neutralising response neutralising responses Novavax NVX NVX-CoV2373 Older Older age outcome Pain participant Participants Pfizer Phase 2 phase 2 trial primary analysis quadrivalent meningococcal conjugate vaccine randomised Randomly ranged reactogenicity referred to Registered Safety SARS-COV-2 infection screened secondary Secondary outcomes Serious Adverse Events Seven spike IgG systemic adverse events the median three group three groups treat treatment allocation Trial Vaccine vaccine availability Valneva Viral viral neutralisation VLA2001 were assessed were blinded white wild-type [DOI] 10.1016/S0140-6736(21)02717-3 PMC 바로가기 [Article Type] Clinical Trial
Prevalence, classification, risk factors and outcome impact of delirium in patients with COVID-19: a meta-analysis protocol for systematic reviewCOVID-19 환자에서 섬망의 유병률, 분류, 위험 요인 및 결과 영향 : 체계적인 검토를위한 메타 분석 프로토콜Article Published on 2021-12-132022-08-31 Journal: BMJ Open [Category] meta-analysis, SARS, [키워드] adult intensive & Adult patients all-cause mortality Analysis association Beijing bioRxiv Characteristics classification Clinical outcome cognitive cognitive disorders. cohort study concerning conducted COVID-19 Critical Critical care database databases delirium delirium & disorders essential element estimate Ethical approval Ethics ethics committee evaluate Evidence evidence of high risk hospitalisation identify inception include institutional review board Intensive ISI medRxiv Meta-analysis meta-regression multivariable outcome Patient patients with COVID-19 peer-reviewed performed Prevalence Previous studies previous study primary and secondary outcomes Primary outcome PROSPERO protocol registration number risk factor Risk factors robustness secondary outcome Secondary outcomes Sensitivity analyses shown Study design Subgroup analyses systematic review Web of Science were used [DOI] 10.1136/bmjopen-2020-048323 PMC 바로가기 [Article Type] Article
Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19고위험 COVID-19 환자의 재입원에 대한 밤라니비맙의 조기 투여와 후기 투여의 영향Observational Study Published on 2021-12-012022-09-11 Journal: The American journal of emergency medicine [Category] MERS, 임상, 진단, 치료제, [키워드] Administered administration Adult patients Analysis bamlanivimab benefit characteristics of patient clinical decompensation Clinical outcome clinical outcomes COVID-19 COVID-19 positive patient COVID-19 positive patients criteria decompensation determine dichotomized emergency department Emergency use authorization EUA expand Future group High-risk COVID-19 hospital Hospitalization ICU Impact in-hospital mortality intensive care intensive care unit less LOS monoclonal antibody monoclonal antibody therapies monoclonal antibody therapy Monoclonal antibody therapy. no difference no differences outcome Patient Primary outcome Prospective Study readmission recombinant retrospective secondary Secondary outcomes Symptom symptom onset the timing therapy Treatment treatment failure two groups [DOI] 10.1016/j.ajem.2021.08.032 PMC 바로가기 [Article Type] Observational Study
Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients코로나19 입원환자 중 INF-β 1-a(인터페론베타-1a)와 IFN-β1-b(인터페론베타-1b) 치료 결과 비교Comparative Study Published on 2021-12-012022-09-11 Journal: International immunopharmacology [Category] SARS, 치료법, 치료제, [키워드] addition Clinical improvement Clinical treatment COVID-19 COVID-19 treatment discharge drug duration of hospitalization Effect evaluated Factors Frequency hospital Hospital stay Hospitalization ICU ICU admission IFN-β IFNβ Inpatient Inpatients interferon interferon beta Interferon beta-1a Interferon beta-1b intervention group intubation Laboratory mechanical ventilation median medication medications Mortality mortality rate no significant difference Other outcomes outcome outcomes patients with COVID-19 Primary outcome recipient recipients Secondary outcomes significant difference statistically significant study group the disease Treatment two group two groups were assessed [DOI] 10.1016/j.intimp.2021.108241 PMC 바로가기 [Article Type] Comparative Study
DrugWAS: Drug-wide Association Studies for COVID-19 Drug RepurposingDrugWAS: COVID-19 약물 용도 변경에 대한 약물 전반의 협회 연구Article Published on 2021-12-012022-09-11 Journal: Clinical Pharmacology and Therapeutics [Category] MERS, 신약개발, [키워드] 95% CI 95% confidence interval Admission Analysis applied association azelastine center clinical trials cohort study coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 diagnosis COVID-19 disease COVID-19 severity death Dextromethorphan diphtheria toxoid drug drugs Efficacy EHR EHR data Electronic health record estradiol ethinyl estradiol exposure to fatty acids Flaxseed fluticasone Health health record ibuprofen identify IMPROVE intensive care intensive care unit list lower risk mechanical ventilation multivariable logistic regression Odds ratio omega-3 Omega-3 fatty acids outcomes overlap pandemic patients with COVID-19 performed pertussis vaccine pneumococcal polysaccharide vaccine Potential treatment Primary outcome Propensity score pseudoephedrine randomized clinical trial repurposing retrospective cohort risk of death secondary Secondary analyses Secondary outcomes significantly tetanus toxoid ubidecarenone university Vaccine Vaccines was selected Weighting [DOI] 10.1002/cpt.2376 PMC 바로가기 [Article Type] Article
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19코로나19로 입원한 환자를 대상으로 한 로피나비르/리토나비르, 로피나비르/리토나비르 + IFN-β-1a 및 히드록시클로로퀸의 효과에 대한 공개 무작위 대조 시험Clinical Trial Published on 2021-12-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] 임상, 치료제, [키워드] 95% confidence interval 95%CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive adjusted odds ratio adults hospitalized age analyses Arm ARMS clinical status conducted Controlled trial coronavirus coronavirus 2019 disease COVID-19 evaluated expected hospitalized patient Hydroxychloroquine Inpatient intention-to-treat population Interferon β-1a IQR Lopinavir LOPINAVIR AND RITONAVIR Lopinavir/ritonavir male median age multicentre no significant effect not improved Occurrence Open-label Ordinal Scale outcome oxygen participant pharmacokinetic plasma concentration Primary outcome quantification Randomized Randomized controlled trial regimen Remdesivir respiratory specimen respiratory specimens respiratory tract specimens Ritonavir SARS-CoV-2 SARS-CoV-2 clearance secondary Secondary outcomes Serious Adverse Event Serious Adverse Events seven-point ordinal scale severe acute respiratory syndrome Coronavirus severe disease significant effect significantly higher solidarity Solidarity trial Standard of care the median the WHO treat Treatment Trial trough ventilatory support Virological with COVID-19 [DOI] 10.1016/j.cmi.2021.05.020 PMC 바로가기 [Article Type] Clinical Trial
Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trialCOVID19로 입원한 환자에 대한 Pentoxifylline 효과: 무작위, 이중 맹검 임상 시험Randomized Controlled Trial Published on 2021-12-012022-09-11 Journal: International immunopharmacology [Category] SARS, 임상, 치료제, [키워드] 1:1 analyzed Anti-inflammatory Anticoagulant antiviral effects assigned baseline changed clinical clinical benefit Clinical characteristics Clinical outcome clinical outcomes clinical trial complications conducted COVID-19 COVID-19 complications demographics dose double-blind Effect Efficacy and safety evaluate Factor glutathione hospital Hospital stay hospitalized patient hospitalized patients Hydroxychloroquine ICU admission IL-6 inclusion criteria individual Inflammation Inflammatory interferon interleukin interleukin-6 intervention group intubation Lopinavir Lopinavir/ritonavir National no significant differences not differ not significant offer oxidative stress Patient patients with COVID-19 Pentoxifylline Placebo placebo group placebo-controlled Primary outcome Randomized randomized clinical trial Randomly recruited regimen Ritonavir safety profile Secondary outcomes Serum level shown significant difference significantly the mean the placebo group two group two groups with COVID-19 [DOI] 10.1016/j.intimp.2021.108227 PMC 바로가기 [Article Type] Randomized Controlled Trial
Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regressionCOVID-19에 대한 회복기 혈장: 메타 분석, 시험 순차 분석 및 메타 회귀Meta-Analysis Published on 2021-12-012022-09-11 Journal: British journal of anaesthesia [Category] 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus adjusted administration angiotensin angiotensin-converting enzyme 2 antibodies association benefit clinical confidence interval convalescent convalescent plasma convalescent plasma treatment coronavirus COVID-19 Disease progression domain evaluate Host host cell host cells ICU admission Interaction mechanical ventilation medRxiv Meta-analysis meta-regression Mild disease Mortality Odds ratio outcome passive immunisation. Patient patients with COVID-19 performed plasma Prevent Primary outcome PROSPERO RCT RCTs receive receptor recruited reduction in Regression risk of death secondary Secondary outcomes sequential analysis severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specific antibodies systematic review titre Treatment Trial trial sequential analysis TSA viral entry viral spike with mild disease [DOI] 10.1016/j.bja.2021.07.033 PMC 바로가기 [Article Type] Meta-Analysis
Incidence of childhood cancer in Canada during the COVID-19 pandemicCOVID-19 전염병 동안 캐나다의 소아암 발병률Article Published on 2021-11-292022-09-11 Journal: CMAJ : Canadian Medical Association journal = jour [Category] SARS, 임상, [키워드] 95% CI 95% confidence interval advanced disease average baseline Canada Cancer cancer type cancers Care change childhood children CIs clinical clinical trial clinical trials conducted COVID-19 COVID-19 pandemic death Diagnosis diagnosis of cancer died enrolled enrolment evaluated Health Health care incidence incidence rate metastatic disease moving average no difference observational study observé oncology outcome pandemic parameter Patient pediatric presenting Primary outcome proportion ranged rate ratio rate ratios reduced resources RRs secondary Secondary outcomes statistically significant stratified Trial [DOI] 10.1503/cmaj.210659 PMC 바로가기 [Article Type] Article
Auricular acupressure for adverse events following immunization related to COVID-19 vaccine injection: study protocol for a multicenter, three-arm, blinded randomized controlled trialCOVID-19 백신 주사와 관련된 예방 접종 후 부작용에 대한 귀지압: 다기관, 3군, 맹검 무작위 대조 시험을 위한 연구 프로토콜Update Published on 2021-11-272022-09-10 Journal: Trials [Category] MERS, SARS, 임상, [키워드] Acupressure therapy adverse event adverse events Analysis assigned association Auricular Auricular acupressure auricular acupressure therapy baseline blinded China clinical COVID-19 COVID-19 vaccine COVID-19 vaccines diarrhoea Efficacy enrolled events fatigue Gastrointestinal headache help immunization inclusion criteria injection injection site intention-to-treat Intervention joint joint pain less local pain multicenter multicentre muscle nausea observation outcome Pain participant per day per-protocol performed primary clinical outcome protocol Randomized Randomized controlled trial Randomly registry reported Result secondary Secondary outcomes significance level single-blind Study design Study protocol therapy three groups Trial Vaccine vomiting [DOI] 10.1186/s13063-021-05837-x PMC 바로가기 [Article Type] Update